The Dynamic Change of Practical Inflammation and Immunity Markers in Cancer Patient Receiving Immune-Enhanced Nutrition during Concurrent Chemoradiotherapy

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20200819005

Enrollment

Unknown

Registered

2020-08-19

Start date

2020-05-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck cancer Esophageal cancer Uterine cervical cancer immunonutrition immune enhancing nutrition radiotherapy NLR Neutrophil to lymphocyte ratio ALC lymphocyte

Interventions

Immunonutrition supplement will be prescribed to patient during chemo&#45

radiotherapy.,Patient will be treated with chemo&#45

radiotherapy without immunonutrition supplement.

Experimental Dietary Supplement,No Intervention No treatment

Immunonutrition supplement,Control

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Nonmetastatic head and neck cancer, esophageal cancer, and cervical cancer patients 2. Age more than 18 years 3. Intended for CCRT either definitive treatment or adjuvant setting 4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

Exclusion criteria

Exclusion criteria: 1. Metastatic disease 2. History of diabetes mellitus, renal disease, and liver disease

Design outcomes

Primary

Measure	Time frame
Neutrophil-to-lymphocyte ratio change between arm initial of CCRT, mid-CCRT, and end of CCRT CBC	—

Secondary

Measure	Time frame
Absolute lymphocyte count change between arm initial of CCRT, mid-CCRT, and end of CCRT CBC	—

Countries

Thailand

Contacts

Public ContactNontiya Homkham

Thammasat University

nontiya.h@fph.tu.ac.th0862147515

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026